Some parts of the portal may cause error messages or display incorrectly due to the transition to a new provider of trading data

ARAV - Aravive, Inc.

IEX Last Trade
0.228
-0.020   -8.947%

Share volume: 6,895,081
Last Updated: Tue 08 Aug 2023 09:59:54 PM CEST
Pharmaceutical Preparation Manufacturing : 2.74%

PREVIOUS CLOSE
CHG
CHG%
$0.25
-0.02
-8.21%
This ticker is disabled and data are no longer maintained and up to date.
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
21%
Profitability 25%
Dept financing 25%
Liquidity 23%
Performance 15%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
0   0%
1 Month
0   0%
3 Months
0   0%
6 Months
0   0%
1 Year
0   0%
2 Year
0   0%
Key data
Stock price
$0.23
P/E Ratio 
0.00
DAY RANGE
N/A - N/A
EPS 
-$0.51
52 WEEK RANGE
$0.00 - $0.00
52 WEEK CHANGE
$0.00
MARKET CAP 
0.000
YIELD 
N/A
SHARES OUTSTANDING 
73.563 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
N/A
BETA 
0.00
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$0
AVERAGE 30 VOLUME 
$0
Company detail
CEO: Gail F. McIntyre
Region: US
Website: aravive.com
Employees: 20
IPO year: 2014
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Preparation Manufacturing
Sector: Manufacturing

Aravive, Inc., a clinical-stage biopharmaceutical company, develops treatments for life-threatening diseases, including cancer and fibrosis. Its lead product candidate is batiraxcept, an ultrahigh-affinity, decoy protein that targets the GAS6-AXL signaling pathway, which is in Phase III clinical trial for the treatment of platinum-resistant recurrent ovarian cancer. The company also develops AVB-S6, a soluble Fc-fusion protein to block the activation of the signaling pathway.

Recent news